Exact Sciences raises $120M to get its cancer test on the market

A week after swaying an FDA panel with its colorectal cancer screen, Exact Sciences ($EXAS) raised $119.7 million through a stock offering, flipping 10 million shares at $12.75 each. With the proceeds, the company plans to pay Cologuard's way through FDA approval, eventually launching the stool-based cancer diagnostic. Release

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.